Home › Funds › CLARK ESTATES INC/NY › STTK
CLARK ESTATES INC/NY position in STTK
SHATTUCK LABS INC · Health Care
CLARK ESTATES INC/NY reported holding 1,416,447 shares of STTK (SHATTUCK LABS INC) in its Q3 2026 13F filing — a position valued at US$9.7M, representing 2.24% of its reported portfolio and ranking #12 among its reported holdings. CLARK ESTATES INC/NY has disclosed STTK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How CLARK ESTATES INC/NY's STTK position evolved
CLARK ESTATES INC/NY first disclosed a stake in STTK in Q3 2023 at 1,475,648 shares (US$2.2M). The position peaked in Q1 2024 at 1,475,648 shares, worth US$13.2M. Across 13 filings, CLARK ESTATES INC/NY increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 10 time(s). The most recent filing (Q3 2026) shows 1,416,447 shares valued at US$9.7M — a reduction of -13,720 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.48M | $2.24M | New |
| Q4 2023 | 1.48M | $10.52M | Hold |
| Q1 2024 | 1.48M | $13.19M | Hold |
| Q2 2024 | 1.48M | $5.70M | Hold |
| Q3 2024 | 1.48M | $5.15M | Hold |
| Q4 2024 | 1.48M | $1.79M | Hold |
| Q1 2025 | 1.48M | $1.40M | Hold |
| Q2 2025 | 1.48M | $1.17M | Hold |
| Q3 2025 | 1.48M | $3.53M | Hold |
| Q4 2025 | 1.48M | $5.39M | Hold |
| Q1 2026 | 1.48M | $9.49M | Hold |
| Q2 2026 | 1.43M | $9.93M | Reduce |
| Q3 2026 | 1.42M | $9.66M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About STTK and 13F data
STTK (SHATTUCK LABS INC) is a Health Care company. 59 other funds we track also report a position in STTK — the largest reported positions include Redmile Group, LLC (US$47.8M), ORBIMED ADVISORS LLC (US$43.8M), Prosight Management, LP (US$41.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding STTK
- Redmile Group, LLC 6.89M sh · $47.83M · Q2 2026
- ORBIMED ADVISORS LLC 6.31M sh · $43.76M · Q2 2026
- Prosight Management, LP 5.96M sh · $41.35M · Q2 2026
- Frazier Life Sciences Management, L.P. 3.75M sh · $26.02M · Q2 2026
- Deep Track Capital, LP 3.71M sh · $25.72M · Q2 2026
- NEXTBio Capital Management LP 3.73M sh · $25.42M · Q3 2026
- Boxer Capital Management, LLC 1.00M sh · $6.94M · Q2 2026
- S&G Foundation 435.75K sh · $2.97M · Q3 2026
- West Tower Group, LLC 191.62K sh · $1.31M · Q3 2026
- LBJ Family Wealth Advisors, Ltd. 82.18K sh · $560.00K · Q3 2026
More on CLARK ESTATES INC/NY
FAQ
How long has CLARK ESTATES INC/NY held STTK?
CLARK ESTATES INC/NY has disclosed STTK holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is CLARK ESTATES INC/NY's current position in STTK?
As of Q3 2026, CLARK ESTATES INC/NY holds 1.42M shares of STTK (SHATTUCK LABS INC), valued at $9.66M, representing 2.24% of its reported portfolio and ranking #12.
Has CLARK ESTATES INC/NY been buying or selling STTK?
In the latest 13F filing (Q3 2026), CLARK ESTATES INC/NY reduced its position in STTK. The position peaked in Q1 2024 at 1.48M shares.
Which other funds hold STTK?
Other major institutional holders of STTK include Redmile Group, LLC, ORBIMED ADVISORS LLC, Prosight Management, LP, among 59 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.